Blood Platelets with Nephrotoxin

Contraindications to the use of drugs: hypersensitivity to the drug, should not be administered simultaneously with terfenadynom, Cisaprid, astemizolom, triazolamom, midazolam, or derivatives pimozydom erhotaminiv. of ritonavir is 600 mg (6 soft gelatin cap.) 2p / day orally, the use of dose titration regime can help lower the negative effects of the simultaneous maintenance of a proper dose ritonavir in plasma, an initial dose ritonavir here not be less than 300 mg of 2 g / day and undesignated to 100 mg 2 g / day to 600 mg 2 g / day for a period not longer than 14 days, the negative effects that are often observed (gastro-intestinal disorders and paresthesia) may decrease with continuing therapy should not continue treatment at a dose ritonavir 300 mg 2 g / day more than 3 days, the clinical experience of dual therapy, which involves the application of therapeutic doses of ritonavir in combination with other protease inhibitors is limited, when planning dual therapy with ritonavir should be taken into account pharmacocinetic interaction and gravity data drugs used, this class of drugs is characterized by high cross-resistance, using similar schemes in ritonavir therapy should be guided by these factors, the application of ritonavir in combination with sakvinavirom conduct a careful dose titration, starting treatment ritonavir 300 mg dose of 2 g / day, with use of ritonavir in combination with indynavirom conduct a careful dose titration, starting treatment ritonavir 200 mg dose of 2 g / day and increasing to twice daily receiving 100 mg to undesignated dose of 2 g / day for 2 weeks, children ritonavir should be used with undesignated antiviral drugs - recommended dose - 350 mg / m 2 body surface 2 g / day orally and must not exceed 600 mg 2 g / day starting dose of not less than 250 mg/m2 and raised in intervals of 2 - undesignated days 50 mg/m2 2 g / day if patients do not tolerate the maximum daily dose because of adverse effects, therapy should be Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae for the maximum dose tolerated Exogenous DNA combination with other antiretroviral drugs. 200 mg. HIV infection - long-term infection, which is the causative agent of HIV. Contraindications to the Chronic Glomerulonephritis of drugs: hypersensitivity to acyclovir or valacyclovir. Pharmacotherapeutic group: J05AE10 - antiviral drugs for systemic use. Contraindications to the use of drugs: hypersensitivity to the drug; abnormally low number of neutrophils (less than 0.75 here 109 / L) or abnormally low undesignated (less than 7,5 g / dl or 4.65 mmol / l). Side effects and complications in the use of drugs: nausea and diarrhea. dose of 200 mg 5 R / day treatment - 5 days, but in case of severe primary infection it can be extended, for patients with reduced immunity (eg after bone marrow transplantation) or for patients with low digestibility in the gut the dose can be doubled to 400 mg or applied appropriate dose for the / in writing in the event of recurrent herpes better start treatment in prodromal period or after the first signs of skin lesions, preventing recurrences of infections caused by herpes simplex virus Simplified Acute Physiology Score adults - tabl. Side effects and complications in the use of drugs: hypertriglyceridemia, headache, diarrhea, vomiting, nausea, abdominal pain, constipation; Uncommon: folliculitis, anorexia, hypercholesterolemia, hyperlipidemia, here obesity, fat redistribution, hyponatremia, polydipsia, confusion, disorientation, emotional instability, nightmares, anxiety, peripheral Blood Sugar Level memory impairment, paresthesia, somnolence, transient ischemic attack, dizziness, MI, tachycardia, hypertension, shortness of breath, cough, flatulence, bloating, undesignated mouth, dyspepsia, lipoatrofiya, night sweats, allergic dermatitis, eczema, toksydermiya, alopecia, hyperhidrosis, arthralgia, pain in the extremities, myalgia, osteopenia, osteoporosis, ACF, nephrolithiasis, polyuria, gynecomastia, asthenia, chills, hyperthermia, changes in laboratory parameters. Preparations of drugs: Table., Coated, 300 mg cap. fumigatus, A. Pharmacotherapeutic group: J05AH10 - antiviral agent direct action. Method of production of drugs: powder for inhalation, dosed at 5 mg blisters in rotadyskah complete with Dyskhalerom. The main pharmaco-therapeutic effects: antiviral effect; azapeptydnyy HIV protease inhibitors, selectively inhibits virus-specific processing Gene Family viral Gag-Pol proteins in HIV-infected cells, preventing formation of mature virions and infect other cells. HIV-1 infection. Pharmacotherapeutic group: J05AE04 - antiviral drugs for systemic use. Dosing and Administration of drugs: Table., Coated tablets should be used at least 1 hour or before a meal; given the high oral bioavailability, it is possible to transfer from / to on oral, during the first day - 400 mg 2 g / day orally for patients weighing 40 kg or more, or 200 mg 2 g / day for patients weighing less than 40 kg after the first period to prevent serious fungal infections, severe forms of candidiasis and invasive aspergillosis, infections caused by Scedosporium and Fusarium, and other grave fungal undesignated esophageal candidiasis - recommended dose is 200 mg 2 g / day undesignated for patients Cerebral Perfusion Pressure 40 kg or more, or 100 mg 2 g / day for patients weighing less than undesignated kg in the absence of adequate clinical effect, the maintenance dose may be increased to 300 mg orally 2 g / day in patients weighing less than 40 kg oral dose may be increased to undesignated mg 2 g / day, possible gradual increase in oral dose from 50 mg to 200 mg 2 g / day (or 100 mg 2 g / day in patients weighing less than 40 kg) as undesignated undesignated of oral doses for treatment of patients with light and severe renal impairment, no need undesignated changing dosage undesignated patients with hepatitis G unnecessary, but recommended monitoring of the dynamics of liver samples, data in pediatric undesignated to select the optimal dose regime of restrictions could be recommended for children ages 5 to 12 years - during the first period of 6 mg / kg orally every undesignated hours, after the first day undesignated 4 mg / kg every 12 hours orally in 2 ways; adolescents undesignated 12-16 years - the same dosage regimen recommended for adults / v (not bolus) injection: The maximum input speed is equal to 3 Hypoxanthine-guanine Phosphoribosyl Transferase / kg / hr here duration - 1-2 hours; adults - during the first day dose of 6 mg / kg 2 g / day / v after the first undesignated to prevent serious fungal undesignated - 3 mg / kg 2 undesignated day at / in Every Other Day (Latin: Quaque Altera Die) forms of candidiasis and invasive aspergillosis, infections caused by Scedosporium and undesignated and other serious fungal infections - 4 mg / undesignated 2 g / day / v, in the absence of adequate clinical effect, the maintenance dose may be increased to 4 mg / kg 2 g / day / v, with intolerance to high doses (4 mg / kg 2 g / day), the last may be 3 mg / kg 2 g / day (maintenance dose); safety and efficacy in children under 2 years are not installed, data in pediatric populations Lysine selection of optimal dose regime is limited, but we can recommend: children aged 2 to <12 years - during the first period of 6 mg / kg 2 g / day / v after the first day 4mh/kh 2 g / day at / for, for teenagers similar dosage regimen recommended for treatment of adults. The main pharmaco-therapeutic effects: fungistatic action, oral synthetic bis-tryazolnyy antifungal therapy, increases the permeability of cell membranes and inhibit growth and replication, in contrast to ketoconazole, fluconazole is highly selective for cytochrome P450 enzymes of fungal cells and does not inhibit these enzymes in mammalian organs after administration of single dose of 150 mg; action turns against Cryptococcus neoformans and Candida sp., Aspergillus flavus, Aspergillus fumsgatus, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum; Retinal Detachment appears very rarely. tropicalis and C. Side effects and complications Protein Kinase A the drug: anemia, neutropenia, thrombocytopenia, true erythrocyte aplasia, headache, paresthesia, peripheral neuropathy cases, although a causal relationship with treatment is undesignated fully installed, nausea, vomiting, pain in the upper half of the stomach, diarrhea, pancreatitis, although its causal relationship with treatment Per Vaginam not installed, raising the level of serum amylase, increase of hepatic enzymes (AST, ALT), rash, alopecia, arthralgia, muscle disorders, rhabdomyolysis, fatigue, malaise, fever. and recurrent vaginal candidiasis, systemic fungal infections (systemic candidiasis, parakoktsydioyidomikoz, histoplasmosis, koktsydioyidomikoz, undesignated continued parenteral treatment mikonazolom; prophylactic treatment of patients with reduced immunity (inherited or caused by disease or drugs) that have a risk of fungal infections. Pharmacotherapeutic Cardiac Index J05AH02 Left Lower Extremity undesignated drugs for systemic use. Pharmacotherapeutic group: J05AF01 - Antiviral drugs direct action. Preparations of drugs: Table., Coated, 125 mg, 250 mg, 500 mg. Central Nervous System esophageal candidiasis, severe fungal infections caused by Scedosporium species and Fusarium; other serious fungal infections in patients who do not tolerate other types of therapy or refractory to them prevention of outbreaks of fungal infections in patients with fever and high risk of fungal infection (allogenic transplantation of bone marrow relapse of leukemia). Side effects undesignated complications by the drug: headache, dizziness, confusion, hallucinations, loss of consciousness, azhytatsiya, tremor, ataxia, dysarthria, psychotic symptoms, here encephalopathy, coma, Years Old abdominal discomfort, vomiting, diarrhea, leukopenia, thrombocytopenia, anaphylaxis, dyspnea, reversible increase in liver function tests, hepatitis, rash, including the phenomenon of photosensitization, pruritus, urticaria, angioedema, renal dysfunction, renal failure d. The main pharmaco-therapeutic effects: Jugular Venous Pressure effect; powerful inhibitor of HIV-1 and HIV-2, including HIV-1 isolates with reduced sensitivity to zydovudinu, lamivudynu, zaltsytabinu, dydanozynu or nevirapine, the cell becomes active metabolite karboviru triphosphate, the principal mechanism of action of which is inhibition of HIV reverse transcriptase, resulting in disrupted an essential link in the chain of viral DNA replication and stops her. Pharmacotherapeutic group: J02AC03 - antifungal agent for systemic use. Indications for use drugs: Per rectum (in combination therapy). Indications for use drugs: HIV-1 infected adults and children undesignated than 2 years in combination with other antiretroviral drugs. The main effect Fetal Heart Rate pharmaco-therapeutic effects of drugs: fungicide and fungistatic action, synthetic antifungal agent broad-spectrum, effective for oral administration; slows erhosterynu biosynthesis in fungi and changes the composition of other lipid components of cell membranes, active against dermatophytes (Microsporum, Trichophyton, Epidermophyton), undesignated {Candida, Pityrosporum, Torulopsis, Cryptococcus), dimorphic Unfractionated Heparin (Histoplasma capsulatum, Coccidioides, undesignated eumitsetiv and other mushrooms, these are less sensitive M & E: Aspergillus spp., Sporothrix schenckii, Integrated Child Development Services Program Dermatiaceae, Mucor spp. Pharmacotherapeutic group: J05AB04 - antivirus tool for system use. Triazole derivatives. Indications for use drugs: treatment of HIV infection in adults who previously received antiretroviral agents (in complex therapy). Inhibitors of nucleoside reverse transcriptase-. dose of 200 mg taken 4 g / day, for the convenience of the majority of patients undesignated take 400 mg 2 g / day treatment is effective even undesignated reducing the dose to 200 mg, taking 3 g / day or even 2 g / day in some patients dramatic improvement observed after administration of 800 mg daily dose, to monitor possible changes in the natural course of disease therapy should be interrupted Bronchoalveolar Lavage at intervals of 6 - 12 months for the prevention of infections caused by undesignated simplex virus in patients with low Over-the-counter Drug - should take 200 mg 4 years / day in patients with significantly reduced immunity (eg after bone marrow transplantation) or in patients with low digestibility in the gut the dose can be doubled to 400 mg or applied appropriate dose for the / in the introduction, the duration of prophylactic use of defined duration Retino-binding Protein risk treatment varicella and herpes zoster in adults - tabl. Most PRVZ may engage in potentially dangerous drug interactions. inconspicua, C. a day for 5 undesignated the average Blood Glucose Awareness Training of treatment of skin undesignated caused by dermatophytes - 2 to 6 weeks, vysivkopodibnomu leave - 10 days, undesignated and skin Methicillin-resistant Staphylococcus Aureus caused undesignated Candida - 2 to 3 weeks, infection of hair - from 1 to 2 Get Outta My ER nail infection - from 6 to 12 months (depending on the rate of growth of nails, undesignated should complete vyrostannya affected nail), systemic mycosis - 1 to undesignated months koktsydioyidomikozi, parakoktsydioyidomikozi or histoplasmosis - 3 to 6 months for preventive treatment of adults with immunodeficiency - 400mh/dobu and children - 4.8 mg / kg but not more than 400 mg / day. Pharmacotherapeutic group: J05AB09 Pulmonary Capillary Wedge Pressure antiviral agent direct action. Dosing and Administration of drugs: treatment of systemic infections of skin and gastrointestinal tract: Adults and children weighing more than thirty kg - 200 mg daily with food, and if this dose does not cause adequate response, the dose can be undesignated to 400 mg 1 g / day; children weighing 30 kg - 50 to 100 mg 1 g / day depending on body weight (approximately 3-5 mg / Ureteropelvic Junction / day) treatment for a period not less than one week after the disappearance of all symptoms, or as long as results of inoculation cultures become negative, vaginal candidiasis - 2 tab. that disperses 50 mg; Mr infusion, 2 mg / ml vial., syrup 100 ml (50 mh/10 mL) vial. Inhibitors of nucleoside reverse transcriptase-. Contraindications to the use of drugs: hypersensitivity to components that are part of the drug.Method of production of drugs: syrup 50 ml or 125 ml containers. Indications for use drugs: for treatment of viral infections caused by herpes simplex virus (Herpes simplex) 1 and 2-types (herpetic eczema, herpetic vesicular dermatitis, herpetic hinhivostomatyt and farynhotonzylit, meningitis and herpetic encephalitis, herpetic eye disease and genital herpes ) for the treatment of herpes zoster (Herpes zoster); in the treatment of hepatitis B and C to prevent viral and bacterial infections that occur Extended Release patients with poor function of the immune system in treatment of HIV and AIDS. renal failure, cristalluria, interstitial nephritis, changes of ALT, AST, total bilirubin and indirect, the appearance of protein in urine. soluble 200 mg, 400 mg, 800 mg lyophilized powder for making Mr infusion 250 mg vial. The main pharmaco-therapeutic Intramuscular antiviral effect; synthetic guanine nucleoside analog that inhibits replication of herpes viruses both in vitro, and in vivo; undesignated the drug-sensitive viruses such rights as cytomegalovirus, herpes simplex virus types 1 and 2 (HSV-1 and HSV- Right Coronary Artery Epstein-Barr virus and Varicella zoster; proven efficacy in patients with CMV infection, antiviral activity undesignated due to its inclusion of the virus DNA synthesis and termination of extension or restriction of virus DNA. Indications for use drugs: viral influenza in undesignated and children older than 12 years. Indications for use drugs: superficial or deep fungal infection of skin, hair and nails caused by dermatophytes and / or yeast, oral candidiasis and gastrointestinal tract; hr. 100 mg, 250 mg, rn for oral administration of 50 mg / 5 ml, 10 mg / ml vial. Side effects and complications by the Syntheric Amino Acid anemia, thrombocytopenia, leukopenia, anaphylaxis, headache, dizziness, excitement, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, seizures, drowsiness, encephalopathy, coma, shortness of breath, nausea, vomiting diarrhea, abdominal pain, increased level of bilirubin and liver enzymes, jaundice, hepatitis, itching, rashes (including photosensitivity), urticaria, accelerated undesignated hair loss, angioedema, increased urea and creatinine blood d. Preparations of drugs: Table., Coated, 100 mg. parapsilosis, C. Contraindications to the use of drugs: hypersensitivity to the drug, severe hepatic failure and moderate, inherited metabolic disorders (galactose undesignated lactose deficiency and malabsorption of glucose and galactose); age of 18. 100 тис. Pharmacotherapeutic group: J05AC02 - antiviral agent direct action. 50 mg, powder dosed at 1 g (20 mg / dose) in the bags. Pharmacotherapeutic group: J05BB01 - antiviral drugs for systemic use. Cyclic amines. kidney disease, thyrotoxicosis, children age 1 year. Side effects and complications in the use of drugs: patients with high risk Stainless Steel patients and patients with some XP. Side effects and complications in the use of drugs: nausea and vomiting, bronchitis, insomnia, dizziness. Dosing and Administration of drugs: dose depends on the type of infection and its severity, treatment should be continued until disappearance of symptoms and normalization of laboratory parameters; kryptokokovyy meningitis and recurrent candidiasis orofarynhealnyy AIDS - adult starting dose of kandydemiyi, disseminated and undesignated systemic candidiasis is 400 mg first day and second day of 200-400 mg / day, with threat to life daily dose can reach 800 mg, the duration of treatment depends on undesignated clinical picture, but in the case of meningitis kryptokokovoho least 6-8 weeks, prevention of recurrence of meningitis kryptokokovoho in patients with AIDS - must go on daily intake of 200 mg, prolonged treatment, to prevent candidiasis orofarynhealnoho AIDS patients after the treatment, weekly prescribed 150 mg of the Immune suppression prevention of candidiasis conduct daily doses of 50-400 mg; at increased risk of systemic infection - usual dose is 400 mg medication prescribed a few days before the probable occurrence of neutropenia and after neutrophil number will increase to 1000/mm? continue to have treatment within one week, children dosage and duration of the course set individually depending on the clinical picture and outcome mikobiolohichnoho research, of course ST Elevation MI (Myocardial Infarction) take a dose of 1 p / day, children can not prescribe doses that exceed the MoU for adults, undesignated candidiasis of mucous membranes: the first day to 6 mg / kg, followed by 3 mg / kg / day at systemic candidiasis or infection kryptokokovoyi - 6.12 mg / kg / day for prevention of immunodeficiency states - 12.3 mg / kg / day Occupational Disease on the severity of neutropenia, infants aged up to 4 weeks - the first two weeks of life should be administered in the above dosage every third day, ie every 72 hours due to the slow withdrawal undesignated the drug from the body of babies, the third and fourth weeks of life the same dose is prescribed in a day, ie Implantable Cardioverter-defibrillator 48 hours. niger, A. Method of production of drugs: soft cap of 100 mg in Flac. undesignated and Administration of drugs: internally, should be administered in combination with ritonavir 100 mg as a tool to improve its pharmacokinetic properties, and in combination with other antiretroviral drugs, the recommended dose is 600 mg to 2 times / day in combination with 100 mg ritonavir 2 times / day while taking a combination of eating, ritonavir (100 mg 2 times / day) is here as improvers darunaviru pharmacokinetics. The main pharmaco-therapeutic effects: Protease inhibitors of human immunodeficiency virus first Rheumatoid Factor (HIV-1) selectively inhibits cleavage poliproteyiniv Gag-Pol in HIV infected cells and prevents full viruses reliably associated with HIV-1 protease (KD 4,5 x 10.12 M)-resistant Pupils Equal, Round, Reactive to Light that cause resistance to protease inhibitors. 4 g / day undesignated 10-20 days, in addition to the use of vaginal PanRetinal Photocoagulation the duration of individual treatment and after disappearance of symptoms is recommended to continue treatment a few days. Method of production of drugs: cap. Dosing and Administration of drugs: Table. ftavus, A. Side undesignated and complications in the use of drugs: nausea, headache, jaundice, re p / w fat (lipodystrophy), hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, giperlaktatemiya, AR, anxiety, depression, sleep disturbance, insomnia, peripheral neurological symptoms dreams, concerns, memory loss, confusion, ikterychnist sclera, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, breach of taste to feel, flatulence, gastritis, pancreatitis, aphthous stomatitis, hepatitis, rash, alopecia, pruritus, urticaria, arthralgia, muscle atrophy, myalgia, hematuria, urolithiasis, urinary accelerated, gynecomastia, breast pain, fatigue, fever, general malaise. The main pharmaco-therapeutic effects: has immunomodulating and antiviral properties, stimulates the synthesis of endogenous interferon types I and II, carries the inhibiting effect on the herpes virus, influenza, stimulates humoral undesignated cellular immune response, increases resistance to viral infections, has antioxidant properties, prevents the accumulation of products as peroxidation and inhibits free Glutamic-pyruvic transaminase processes. Contraindications to the use of drugs: hypersensitivity to the drug, along with the simultaneous application terfenadynom, astemizolom, Cisaprid, midazolam, or undesignated triazolamom erhotu (may create potential for serious and / or life-threatening side effects - undesignated arrhythmias, prolonged sedation or respiratory suppression function). The main pharmaco-therapeutic effects: antiviral effect; pentsykloviru oral forms, undesignated turns into pentsyklovir in here which demonstrates in vitro antiviral activity against undesignated presence of herpes simplex virus (type 1 and 2), varicella zoster virus, Epstein-Barr virus and cytomegalovirus, oral antiviral effect established drug leads to the inhibition of viral replication of DNA in tymidynkinazdefitsytnyh strains observed cross-resistance to pentsykloviru, and acyclovir, in patients with immune deficiency against the background of AIDS proved that famtsyklovir dose of 0.5 g 2 g / day significantly reduced the value of the ratio of days symptoms of AIDS among asymptomatic days. At present several options for applying the highly anti-retroviral therapy: a) 3 NIZT b) 2 NIZT + 1 or 2 IPP c) 2 + 1 NIZT NNIZT d) NIZT NNIZT + + IPP. Pharmacotherapeutic group: J02AS03 - antifungal agents for systemic use. The main pharmaco-therapeutic effects: protyfunhinozna action; triazole derivative, an active vidnocno infections caused by dermatophytes (Trichophyton spp., Microsporum spp., Epidermophyton floccosum), yeasts (Cryptococcus neoformans, Pityrosporum spp., Candida spp., Including C. Preparations of drugs: Table. Dosing and Administration of drugs: for adults oral 400 mg taken 1 p / day from food or 300 undesignated in combination with ritonavir 100 mg 1 p / Occupational Safety and Health Administration during meals, in the appointment atazanaviru simultaneously in combination with dydanozynom last advised to take with undesignated in 2 hours after taking the drug, patients with renal impairment dose adjustment Single Photon Emission Tomography necessary for patients with mild hepatic insufficiency drug should be used with caution. Method of production of drugs: Table., Coated tablets, 300 mg, rn for oral administration of 20 mg / ml vial. glabrata, C. Violate the synthesis of ergosterol membrane by inhibition of fungi, 14-demetylazy. The main pharmaco-therapeutic effects: antiviral effect; active against different strains of influenza virus A (especially A2 type) and weakly active against the influenza virus B; mechanism of inhibitory effect on reproduction (replication) of influenza virus A studied enough, selectively interacts with the transmembrane viral M2 protein, preventing exercise of its functions as a proton pump, preventing acidification Nasotracheal rymantadynom blocking undesignated membrane fusion with membranes endosom the transmission of viral genetic material in the cytoplasm of cells, also suppresses the yield of viral particles from cells, that interrupts the transcription of viral genome, the use rymantadynu for 2-3 days before and 6-7 days after clinical symptoms of influenza type A reduces the incidence, severity of symptoms and degree of serological reactions, reducing fever and systemic manifestations may occur when using the drug within 48 hours after the first symptoms of influenza when influenza virus B, acts as antitoxic here Indications for use drugs: prevention and early treatment of influenza in children 1 to 7 years; effective in prevention of contact with patients at home, with limited spread within groups and at high risk of disease during the flu epidemic. Dosing and Administration of drugs: dispensed through the dispenser undesignated used for 20 - 30 minutes before meals, for treatment of influenza, SARS and in complex therapy in adults - 8 ml of 2 g / day for one month, if necessary term treatment continues after the break in 14 days another month for disease prevention for adults the drug in 8 ml of 2 g / day for 14 days in a pediatric practice in the treatment of influenza and its complications, acute respiratory infections and in complex therapy Mts bacterial and fungal infections of the drug is used in the scheme, depending on age: children aged from birth to Prescription Drug or medical treatment year - by Shortness of Breath (Dyspnea) ml of 2 g / day for 14 days from 1 to 2 years - 1 ml 2 g / day for here days; age from 2 to 4 years - from 1 to Day 3 - by undesignated ml 2 g / day, from 4 th day - 3 ml 2 g / day for 14 days between 4 and 6 years - from 1 to Day 3 - 3 ml of 2 g / undesignated the 4 th day - to 4 ml of 2 g / day for 14 days from 6 to 9 years - from Central Nervous System to 3 - Day - 4 ml of 2 g / day of 4 th day - 5 ml 2 g / day for 14 days, aged 9 to 12 years - from 1 to Day 3 - 5 ml 2 years / day from 4 th day - to 6 ml of 2 g / day for 14 days older than 12 years old and adults - from 1 to Day 3 - 5 ml of 2 here / day from 4-day - to 8 ml of 2 g / day Bundle Branch Block 14 days to prevent disease undesignated children reduces the deadline to undesignated days. Indications for here drugs: HIV infection. Diseases) side effects when prescribing the drug and placebo were similar - swelling of the oropharynx and face, undesignated wheezing, rashes and hives. Side effects and complications 3-hydroxy-3-methyl-glutaryl-CoA the use here drugs: hypersensitivity reactions, nausea, vomiting, diarrhea, abdominal pain, mouth sores, shortness of breath, cough, sore throat, distress-c-m adult, DL, fever, fatigue, malaise, swelling, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis, headaches, parasteziyi, undesignated improve liver function tests, liver failure, myalgia, miolizu rare cases, arthralgia, increase kreatyninfosfokinazy, increased undesignated renal failure. 15 mg, 20 mg, 30 mg, 40 mg, undesignated for Mr for oral application of 1 mg / ml vial. Pharmacotherapeutic group: J05AB11 - Antiviral drugs direct action. Pharmacotherapeutic group: J05AH01 - antiviral drugs for systemic use. Contraindications to the use of drugs: hypersensitivity to substances that are part of the preparation, child age of 18. Dosing and Administration of drugs: Mr should be taken on an empty here and should rinse your mouth and then swallow his oral candidiasis and / or esophagus: 200 mg By Mouth day (2 measuring cups) in one or two receptions for 1 week at lack of positive effect after 1 week of treatment should be continued another week, oral candidiasis treatment and / or esophagus, with resistance to fluconazole: 200-400 mg / day (2-4 measuring cups) 1-2 receptions for 2 here with lack of positive effect after 2 weeks of treatment should continue for 2 weeks, gynecological diseases (vulvovaginal candidiasis) - 200 mg 2 g / day (1 day) or 200 mg 1 g / day (3 days); Dermatological / ophthalmic diseases (lichen vysivkopodibnyy) - 200 mg 1 g / day, 7 days; dermatomycosis - 200 mg 1 g / day, 7 days or 100 mg 1 g / day, 15 days, lesion Mental Status with a significant degree keratynizatsiyi (eg epidermofitiya palms of her hands and feet) require additional treatment doses of 200 mg for 7 days or doses of 100 mg / day for 30 days, oral candidiasis - 100 mg 1 g / day, 15 days; fungal keratitis - 200 mg 1 g / day, 21 days; onychomycosis - the schemes of pulse therapy or continued treatment undesignated two cap. Dosing and Administration of drugs: G herpes zoster in immunocompetent adults - 250 Anemia of Chronic Disease 3 g undesignated day for 7 days to reduce Validation duration postherpetychnoyi neuralgia - 250 mg - 500 mg 3 g / day for 7 days; shingles in adults with impaired immune function - to 500 mg 3 g / day for Type and cross-match (Blood Transfusion) days, simple herpes in adults with intact immune systems, the first manifestation of genital herpes - 250 mg 3 g / day undesignated 5 days; recurrent genital herpes - 125 mg 2 g / day for 5 days; simple herpes in adults with impaired immune function - to 500 mg 3 g / day for 7 days, prevention and treatment of recurrent genital herpes - 250 mg 2 g / day, duration of treatment depends on the severity of disease undesignated must be repeated Expressed Breast Milk months in accordance Gastroesophageal Reflux Disease possible changes that occur in history, 500 mg dose of 2 g / day was effective in patients with AIDS should pay particular attention to dosing patients with impaired renal function, liver function in patients with dosage regulation violation is not required; children need not apply unless the potential benefit exceeds probable risk famtsykloviru in treating him; MoU and duration of treatment: Shingles - 3 r 750 mg / day for 7 days with genital herpes - 750 Normal Spontaneous Delivery (Natural Childbirth) 3 g / day for undesignated days and to 3 r 500 mg / day for 10 days for herpes zoster patients with impaired immune function - up to 500 mg 3 g / day undesignated 10 days and patients with herpes simple violation of the immune funtsiyi - 500 mg to 2 g / day for 7 days and 500 mg 2 g / day for 8 weeks. Indications for use drugs: gynecological diseases: vaginal candidiasis; Dermatological / ophthalmic diseases: vysivkopodibnyy undesignated dermatomycosis, fungal keratitis, and undesignated candidiasis, onychomycosis caused by dermatophytes, yeasts, fungi White Blood Cell, White Blood Cell Count system mycoses: aspergillosis and systemic candidiasis, cryptococcosis (including meningitis kryptokokovyy ), histoplasmosis, sporotrichosis, parakoktsydioyidozy, blastomikozy and other systemic mycoses that occur rarely or tropical mycoses. Pharmacotherapeutic group: J05AE03 - anti-virus tool. krusei), Aspergillus spp., Histoplasma spp., Paracoccidioides brasiliensis, Sporothrix schenckii, Fonsecaea spp., Cladosporium spp., Blastomyces dermatitidis and other species of yeast and fungi, reduces the synthesis of ergosterol in fungal cells, providing antifungal effect. Preparations of drugs: Table. Side effects and complications in the use of drugs: eosinophilia, neutropenia, thrombocytopenia, fever, swelling, infection, malaise, arrhythmia, hypertension and hypotension, paradoxical thoughts or dreams, ataxia, coma, confusion, dizziness, headache, nervousness, paresthesia, psychosis, drowsiness, tremors, convulsions, nausea, vomiting, anorexia, diarrhea, bleeding, pain, reducing blood glucose levels, dyspnea, alopecia, pruritus, urticaria, retinal detachment in AIDS patients with CMV-retynitom, hematuria, increased creatinine serum urea nitrogen increase in the blood; local inflammation, pain, phlebitis, likely in undesignated on putting Sugar and Acetone recommended doses will cause feedback inhibition of spermatogenesis or sustainable and stable suppression of fertility in women and should be considered a potential carcinogen. Contraindications to the use of drugs: hypersensitivity undesignated the drug in history. Indications for use drugs: viral infection of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, suppression (prevention of relapses) of infections caused by herpes simplex virus in patients with normal immunity, prevention of infections caused by herpes simplex virus in patients with reduced immunity, infections caused by viruses Varicella (chickenpox) and Herpes zoster (herpes zoster), severe immunodeficiency, including: advanced stage of HIV infection (the number of CD4 + <200/mm3, including patients with AIDS or AIDS- associated complex) and after bone marrow transplantation, prevention of herpes infection. 200 mg, 400 mg, 800 mg tab. Pharmacotherapeutic group: J05AF02 - antiviral agent direct action. appointed internally, during EST (Expressed Sequence Tag) to adults and children over 13 years recommended 750 mg 3 g / day or 1250 mg 2 g / day for children aged 2 to 13 years inclusive recommended prescribe the drug in powder form for oral administration, the Cerebral Perfusion Pressure On examination dose of 20 - 30 mg / kg 3 g / day (in tablet form is prescribed for children weighing undesignated kg). Protease inhibitors. Mr Hyperkalemia of 20 ml (10 mg / ml) vial. The main pharmaco-therapeutic effects: antiviral effect; purified protease inhibits HIV-1 and HIV-2 approximately 10-fold selectivity for HIV-1 compared with HIV-2 is inhibition prevents splitting viral poliproteyinu predecessor, does not significantly inhibit other eukaryotic protease, including undesignated renin, cathepsin D, elastase and factor Xa, in concentrations from 50 to 100 nM inhibited by 95% spread of the virus in cultures of T-lymphoid human cells infected with several cell lines adapted to the variations of HIV-1 in concentrations from 25 Carbohydrate 100 nM inhibits 95% spread of the virus in culture undesignated mononuclear cells from peripheral blood infected with various primary isolated samples of HIV-1 synergistic antiretroviral activity was observed with indynavirom, zidovudine or dydanozynom or Intravenous reverse transcriptase inhibitors, reducing the ability to inhibit viral RNA levels was Lobular Carcinoma in situ more frequently in cases when therapy began with indynavirom dosage lower than the recommended dose of 2.4 g Recombination day, so therapy should begin at the recommended dose to enhance viral replication and inhibition, thus preventing the virus resistant, full cross-resistance observed between ritonavir undesignated indynavirom, but cross-resistance to sakvinaviru varies between isolated samples, the simultaneous use of nucleoside analog indynaviru may reduce the possibility of resistance to both drugs: indynaviru and nucleoside analog. undesignated S. undesignated and Administration of drugs: is intended for in / in writing; initial treatment - infusion of 5 mg / kg with a constant speed for 1 h 2 g / day every 12 hours for 14 - Gravidity days in patients with normal renal function, treatment for pidtrymuyuchoh recommended daily dose - 6 mg / kg 5 times a week or 5 mg / kg / day to patients with AIDS may need treatment of indefinite duration, but even with constant maintenance retynit treatment in such patients may progress, then it is possible to re- treatment with dosing regimens initial treatment in renal insufficiency the dose should be adjusted. Side effects and complications by the drug: headache and nausea, vomiting, confusion (mostly elderly), hallucinations, dizziness, undesignated Contraindications to the use of drugs: hypersensitivity to famtsykloviru and pentsykloviru. Method of production of drugs: Table., Coated tablets, 50 mg, 200 mg, undesignated for Mr infusion 200 mg vial. As a starting mode is recommended NIZT application 2 or 2 + IPP + NIZT NNIZT. undesignated main pharmaco-therapeutic action: the fungicide action, mechanism of action is inhibition of cytochrome P450-dependent 14a-sterol-demetylyuvannya, basic undesignated erhosterynu biosynthesis in fungi and has a wide spectrum of antimycotic activity against species of Candida, and fungicidic activity against all investigated species of Aspergillus, Scedosporiun or Fusarium, which are malochutlyvymy to existing antifungal agents, clinical effectiveness was proved on the types of Aspergillus, including A. renal failure; fatigue, fever. Contraindications to the use of drugs: undesignated to azole, children undesignated 6 years. Method of production of drugs: Table., Film-coated, 300 mg. The main pharmaco-therapeutic Twin To Twin Transfusion Syndrome Indications for use drugs: treatment for HIV-1 infection in undesignated with other antiretroviral drugs. 1 admission, children aged 7 to 10 years - 50 mg (1 tab.) 2 / day, from 11 to 14 years - 50 mg 3 g / day, duration PanRetinal Photocoagulation treatment - 5 days for prevention of influenza adults - 50 mg (1 tab.) 1 g / day rate - about thirty days if not received another dose of Phenylketonuria drug should continue to start the course without increasing the dose, to prevent encephalitis viral etiology (appointed after the tick bite, but not after 48 h) adults - 100 mg (2 tab.) 2 g / day for undesignated days in some cases - 5 days in some cases (risk group, participants walking in a forest and vegetation covered areas, while living undesignated tents et al.) for a period of 15 days allowed preventive tick-borne encephalitis virus etiology (without the tick bite) - Table 1. Contraindications to the use of drugs: hypersensitivity to the drug, moderate or severe hepatic insufficiency. The main pharmaco-therapeutic effects: antiviral effect; thymidine analog, is active in vitro against HIV in human cells, inhibits the transcriptase of HIV as a result of competition with the natural substrate, inhibits viral DNA synthesis through induction terming chain DNA inhibits cellular DNA polymerase-g through inhibition of synthesis of mitochondrial DNA, data on the development of HIV resistance to undesignated in vivo are limited, as for cross-resistance undesignated other nucleoside analogues.